Stocks in news: CEMEX, S.A.B. de C.V. (NYSE:CX), Exact Sciences (NASDAQ:EXAS), Elizabeth Arden (NASDAQ:RDEN), Ligand Pharmaceuticals (NASDAQ:LGND), Regency Energy Partners (NYSE:RGP)

CEMEX, S.A.B. de C.V. (NYSE:CX) announced Operating EBITDA on a like-to-like basis increased by 16% during the quarter to U.S.$701. On a like-to-like basis, full-year operating EBITDA increased by 6% to U.S.$2.7 billion. Operating EBITDA margin grew by 1.7 percentage points on a year-over-year basis reaching 18.3%. For the full year 2014, operating EBITDA margin remained flat at 17.4% versus the comparable period in 2013.On Friday shares of CEMEX, S.A.B. de C.V. (NYSE:CX) closed at $9.90. Company’s sales growth for last 5 years was -2.80% and EPS growth for next 5 years is recorded as 2.40%.

Exact Sciences Corporation (NASDAQ:EXAS) and Mayo Clinic announced a five-year extension and expansion of their collaboration, broadening their efforts to develop screening, surveillance and diagnostic tests beyond colorectal cancer to address other diseases within the gastrointestinal tract. Exact Sciences Corporation (NASDAQ:EXAS) in last trading activity moved down -1.45% to close at $27.81. Company weekly performance is 2.21% while its quarterly performance stands at 19.72%. Exact Sciences Corporation (NASDAQ:EXAS) is -7.21% away from its 52 week high.

Elizabeth Arden (NASDAQ: RDEN) reported Q2 EPS of $0.28, $0.31 worse than the analyst estimate of $0.59. Revenue for the quarter came in at $333.6 million versus the consensus estimate of $366.5 million. On last trading day Elizabeth Arden, Inc. (NASDAQ:RDEN) moved down -3.19% to close at $14.89. Its volatility for the week is 5.55% while volatility for the month is 5.04%. RDEN’s sales growth for past 5 years was 1.70% and its EPS growth for past 5 years was 12.56%. Elizabeth Arden, Inc. (NASDAQ:RDEN) monthly performance is -16.77%.

On 3 February, Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced it signed a license agreement with Sermonix Pharmaceuticals LLC for the development and commercialization of oral lasofoxifene in the United States and additional territories. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has 2.20% insider ownership while its institutional ownership stands at 94.10%. In last trading activity company’s stock closed at $54.99.

Regency Energy Partners LP (NYSE:RGP) and its directors were hit with a proposed class action in Texas federal court on 3 February over the company’s $11.2 billion sale to Energy Transfer Partners LP, valued at $18 billion after debt and liabilities, alleging the sale was reached by unfair means and at an unfair price. On last trading day Regency Energy Partners LP (NYSE:RGP) moved down -1.01% to close at $24.40. Its volatility for the week is 3.09% while volatility for the month is 4.23%. RGP’s sales growth for past 5 years was 7.10% and its EPS growth for past 5 years was -31.00%. Regency Energy Partners LP (NYSE:RGP) monthly performance is 8.83%.

Leave a Reply

Your email address will not be published. Required fields are marked *